Loading stock data…
Intellia Therapeutics, Inc. (NTLA)
$16.61-0.07 (-0.42%)
After Hours$16.54-0.07 (-0.42%)· Last close Jun 29
Intellia Therapeutics, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Intellia Therapeutics, Inc. in the Healthcare sector is trading at $16.61 with a market capitalization of $2.3B. Wall Street consensus targets $26.63 (19 analysts), implying a +60.3% move over the next 12 months. The stock is currently 41% below its 52-week high of $28.25, remaining 22.2% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +60.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $15.05M↓ | $23.02M↑ | $13.78M↓ | $14.24M↓ | $16.63M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$100.53M↓ | -$98.71M↑ | -$111.48M↓ | -$110.00M↑ | -$120.81M |
| Net Income | -$96.23M↓ | -$95.79M↑ | -$101.32M | -$101.25M↑ | -$114.33M |
Peer Comparison
JNJUNHPFE
Fundamentals
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeat...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.32B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-63.55%
Volume
Today's trading volume
5.57M
Recent News
Strength Seen in Mirum Pharmaceuticals (MIRM): Can Its 5.5% Jump Turn into More Strength?
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare.
This Stock Is Up 58% This Year. Is It too Late to Buy?
There could be additional catalysts for this drugmaker over the next year.
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.